Who should read this?
People with newly diagnosed metastatic hormone-sensitive prostate cancer who carry a BRCA1 or BRCA2 mutation (in the tumour or inherited), and anyone being offered or considering a PARP-inhibitor trial.
Which cancer is this about?
This study focuses on metastatic hormone-sensitive prostate cancer (mHSPC) in people whose cancer has a BRCA1 or BRCA2 alteration.
Why this matters
BRCA1/2 mutations affect the cancer’s ability to repair DNA damage. This can make these cancers more sensitive to PARP inhibitors, a class of drugs already used later in prostate cancer treatment.
AMPLITUDE is testing whether adding a PARP inhibitor earlier, before the cancer becomes hormone-resistant, can improve outcomes.
Treatment studied
The trial is comparing:
• Niraparib + abiraterone + ADT
versus
• Abiraterone + ADT alone
(Exact treatment schedules vary by trial arm and region.)
Results
AMPLITUDE is ongoing.
At the time of this entry, mature efficacy results and hazard ratios for progression-free survival and overall survival have not yet been released.
These results will be updated when published.
Key takeaway
Test early for BRCA1/2 mutations. Tumour (somatic) and, where appropriate, inherited genetic testing at diagnosis is essential to identify people who may benefit from early treatment escalation or clinical trials.
AMPLITUDE is a major study asking whether adding a PARP inhibitor early can improve outcomes in BRCA-mutated mHSPC. The potential is high, but the definitive benefit will depend on the final hazard ratio results when the trial reports.